Proportion of patients with an undetectable pVL after (re)initiation of long-term cART over a period of 144 weeks in naive and early treated patients.

<p>Proportion of patients with an undetectable pVL after (re)initiation of long-term cART over a period of 144 weeks in naive and early treated patients.</p

Patient characteristics at (re)initiation of long-term cART.

<p>Data are n (%) unless indicated otherwise. MSM, men who have sex with men; PHI, primary HIV infection.</p>‡<p>9 missing patients: 3 in the non-early treated and 6 in the early treated group.</p

Viral decay after treatment initiation of early cART and subsequent long-term cART in the early treated patients.

<p>Viral decay after treatment initiation of early cART and subsequent long-term cART in the early treated patients.</p

Viral decay after treatment (re)initiation of long-term cART in naive and early treated patients.

<p>Viral decay after treatment (re)initiation of long-term cART in naive and early treated patients.</p

CD4 count recovery after treatment (re)initiation of long-term cART in naive and early treated patients.

<p>CD4 count recovery after treatment (re)initiation of long-term cART in naive and early treated patients.</p

Plasma viral load and CD4 cell count after randomization/treatment interruption in the no treatment and treatment arms.

<p>Modeled mean pVL (A) and CD4 cell count (B) over time after randomization/TI in the no treatment and the 24- and 60-wk treatment arms for the group of patients randomized over the three study arms. Graphs show the estimates (± standard error of the mean) from the linear mixed models. The box below each graph shows the number of pVL and CD4 cell count measurements at each time point used for fitting the linear mixed models. c/ml, copies/ml.</p

Baseline characteristics of 115 patients randomized over three study arms.

<p>Data are <i>n</i> (percent) unless indicated otherwise.</p>a<p>16 patients with missing data.</p>b<p>51 patients with missing data.</p>c<p>65 patients with missing data.</p>d<p>60 patients with missing data.</p><p>MSM, men who have sex with men; n.a., not applicable.</p

Characteristics of the study populations.

†<p>NP  =  Not Performed;</p>*<p>Consumption per capita per year in USD corrected for purchasing power parity (PPP), 2009 conversion rate World bank (<a href="http://www.worldbank.org/" target="_blank">http://www.worldbank.org/</a>).</p

Prevalence of Hypertension and other CVD risk factors.

*<p>HT  =  hypertension;</p>†<p>In those with untreated or inadequately treated hypertension;</p>¶<p>WHO CVD risk charts start at age 40 years and older;</p>¶¶<p>Those with blood pressure ≥160/100 mmHg or 140/90 and 10 year CVD risk of ≥20%;</p>**<p>SBP  =  systolic blood pressure, DBP  =  diastolic blood pressure;</p>∥|<p>NP =  not performed;</p>††<p>BMI  =  Body Mass Index;</p>‡<p>WC  =  waist circumference, M  =  male, F  =  female;</p>&par<p>DM  = Diabetes Mellitus (non-fasting blood glucose of ≥11.1 mmol/L, or a fasting blood glucose of ≥7.0 mmol/L, or self reported use of drug treatment for DM);</p>§<p>High cholesterol ≥6.2 mmol/L;</p>§§<p>U = 1 standard unit of alcohol containing approximately 10 g of ethanol;</p>***<p>Reported parent with hypertension, diabetes or heart disease.</p

Awareness, treatment and blood pressure control in patients with hypertension.

<p>Definitions: Aware  =  respondents who self report to have hypertension, Treated  =  respondents who self report to have hypertension, and who indicate to take drug treatment for hypertension, Controlled  =  respondents who self report to have hypertension, and who have a blood pressure below 140/90 (patients who use drug treatment or for whom treatment status is unknown).</p